Jonzo 

i agree 100% that Zenith is the much much much better bet for a BP or Royalty based company deal with most of all their trials being open label oncology trials. 13 trials are currently ongoing and with some of the most prestigious health care centers and BP involved in clinical collaboration, 

I think the Nut Carcinoma trial with 60% ORR has to be a big interest to someone trying to till the drug Pipeline...

as for RVX getting funding from a Zenith deal I am all for it as long DM is not involved in any the trials, he has been only been a disappointment and hinderance to RVX science potential.. bring on new and experienced management and I will get some interest back in RVX